Sundar SS, Knott CS, Paley L, et al. Significant variation in treatment and survival outcomes in stage 2–4 ovarian cancer in England: results from the national Ovarian Cancer Feasibility Audit Pilot. Int J Gynecol Canc 2020; 30:A133-A134. https://ijgc.bmj.com/content/30/Suppl_4/A133.2
Abstract:
Introduction/Background Complete cytoreductive surgery and platinum-based chemotherapy is standard of care in the United Kingdom (NICE, 2011), yet studies indicate substantial variation in the utilization of both (Kumar et al, 2016, Hall et al). Recent work from the Netherlands shows variations in treatment for ovarian cancer across regions; however, contribution to survival was unclear (Timmermans et al, 2019). Care that is not compliant with guidelines is also seen in other countries, including the USA (Warren et al, 2017).
As part of the Ovarian Cancer Audit Feasibility Pilot, geographic variation in treatment was investigated with the objective of informing improvements in treatment and outcomes for all women diagnosed with ovarian cancer in England.